首页> 外文期刊>Journal of Medicinal Chemistry >Pt(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position
【24h】

Pt(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position

机译:轴向位置含有非甾体抗炎药的 Pt(IV) 前药

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We report herein the design, synthesis, and biological investigation of a series of novel Pt(IV) prodrugs with nonsteroidal anti-inflammatory drugs naproxen, diclofenac, and flurbiprofen, as well as these with stearic acid in the axial position. Six Pt(IV) prodrugs 5-10 were designed, which showed superior antiproliferative activity compared to cisplatin as well as an ability to overcome tumor cell line resistance to cisplatin. By tuning the drug lipophilicity via variation of the axial ligands, the most potent Pt(IV) prodrug 7 was obtained, with an enhanced cellular accumulation of up to 153-fold that of cisplatin and nanomolar cytotoxicity both in 2D and 3D cell cultures. Pt2+ species were detected at different depths of MCF-7 spheroids after incubation with Pt(IV) prodrugs using a Pt-coated carbon nanoelectrode. Cisplatin accumulation in vivo in the murine mammary EMT6 tumor tissue of BALB/c mice after Pt(IV) prodrug injection was proved electrochemically as well. The drug tolerance study on BALB/c mice showed good tolerance of 7 in doses up to 8 mg/kg.
机译:本文报道了一系列新型Pt(IV)前药的设计、合成和生物学研究,这些前药含有非甾体抗炎药萘普生、双氯芬酸和氟比洛芬,以及轴向位置的硬脂酸。设计了6种Pt(IV)前药5-10,与顺铂相比,其显示出优异的抗增殖活性,以及克服肿瘤细胞系对顺铂耐药的能力。通过改变轴向配体来调节药物亲脂性,获得了最有效的 Pt(IV) 前药 7,在 2D 和 3D 细胞培养中,细胞积累增强至顺铂的 153 倍,并且具有纳摩尔细胞毒性。使用Pt包覆的碳纳米电极与Pt(IV)前药孵育后,在MCF-7球体的不同深度检测到Pt2+物种。顺铂在BALB/c小鼠乳腺EMT6肿瘤组织中的体内积累也被电化学证明。对BALB / c小鼠的药物耐受性研究显示,在高达8mg / kg的剂量下,耐受性为7。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号